Gidi Littwin, an inventor of Apple’s Face ID, is now pitching a new way to look at the brain: Hemispheric, an AI startup that creates diagnostic brain scans. The company targets conditions that range from psychiatric to neurological, including depression, PTSD, and Parkinson’s. And the big promise is not just “better imaging,” it is a complete workflow makeover, with diagnostic scans made as cheap and easy as a blood test.

That “blood test level” ambition matters because it goes after the real bottleneck in brain health. Right now, diagnosing many brain-related conditions typically requires expensive, time-consuming steps. Hemispheric’s approach is positioned as AI-driven scans that could bring the process down to something closer to routine clinical testing. In other words, Littwin is trying to turn what is often a specialist-heavy, costly diagnostic path into something primary-care and routine-care could actually absorb.

To understand why this is a board-level deal and not just a technology story, zoom out to how diagnostic markets usually scale. Imaging and lab diagnostics often win when they reduce barriers: lower costs, faster turnaround, simpler administration, and clearer clinical usefulness. The moment a diagnostic tool becomes easy to order and interpret, adoption stops being limited by logistics and starts being limited by outcomes. That is the core execution problem Hemispheric is implicitly taking on: not only producing diagnostic accuracy with AI, but also packaging it into a process that clinicians can use without adding friction.

There is also an incentive shift baked into the pitch. If Hemispheric can truly make brain scans feel like a blood test, then the market expands beyond neurologists and psychiatrists. More clinicians could screen more people, earlier in a disease timeline. Earlier detection is often where the downstream economics become compelling: fewer late-stage interventions, better care planning, and potentially more standardized pathways for treatment. Even if the initial deployment is limited to certain settings, a “low friction” strategy changes how quickly a diagnostic product can move from pilots to scale.

Regulatory framing is another reason the “cheap and easy” goal is not trivial. Brain-related diagnostics sit at the intersection of medical devices, clinical decision support, and the broader push to validate AI in real-world care. Regulators generally care about two things: whether the tool is safe and effective, and whether it performs reliably across the messy reality of different patients, scanners, and clinical contexts. Hemispheric’s reliance on AI makes validation even more central, because the system must generalize beyond the conditions it was trained or tested on.

That matters strategically for investors and healthcare operators watching from the sidelines. A credible path to approval and adoption usually requires evidence that stands up not only in controlled studies, but also in clinical workflows. The “blood test like” aspiration sets a high bar, because cheap and easy often implies streamlined inputs and outputs, meaning the company has to prove utility with minimal operational complexity. If Hemispheric can do that, it could unlock a broader reimbursement and procurement conversation. If it cannot, the product risks becoming another promising modality stuck in expensive, narrow-use cases.

Finally, this launch is a signal to a wider crowd. In this space, the most valuable companies are often the ones that turn advanced computation into everyday medicine. Littwin’s Face ID background is notable, because it suggests an instinct for turning complex detection into fast consumer-grade experiences. In healthcare, that translation is harder but potentially transformative. If Hemispheric succeeds at diagnosing depression, PTSD, and Parkinson’s through AI-driven brain scans that are designed to be as cheap and easy as a blood test, it could reshape expectations for what “medical-grade intelligence” should feel like at the point of care.